Key Highlights
- Third-quarter 2026 net loss was USD 44.3 million, or USD 0.76 per share.
- Acquired in-process Research and Development expense was USD 35.0 million.
- The company closed a USD 105.0 million milestone and Royalty financing with HCRx.
- Cash and cash equivalents were USD 107.9 million at September 30, 2026.
Spero Therapeutics (NASDAQ:SPRO) reported a third-quarter 2026 net loss of USD 44.3 million, or USD 0.76 per share, against an estimate of a loss of USD 0.47 per share, in its Quarterly Report on Form 10-Q. The company reported no Revenue in the quarter. It describes itself as a clinical-stage biopharmaceutical company focused on next-generation medicines for immune-mediated diseases.
Quarterly Results
Total revenues were zero for the three months ended September 30, 2026, against USD 5.4 million a year earlier, which consisted of grant revenue of USD 2.4 million and related-party collaboration revenue of USD 3.0 million. For the nine months, total revenues were USD 258 thousand, against USD 25.5 million.
Acquired in-process research and development expense was USD 35.0 million. Research and development expenses were USD 3.2 million, against USD 8.6 million, and general and administrative expenses were USD 3.7 million, against USD 4.2 million. Total operating expenses were USD 41.9 million, against USD 13.4 million, and the loss from operations was USD 41.9 million, against USD 7.9 million.
Interest income was USD 0.9 million, against USD 0.5 million. Interest expense related to the sale of future milestones and royalties was USD 3.3 million. Net loss was USD 44.3 million, against USD 7.4 million a year earlier. For the nine months, net loss was USD 61.0 million, or USD 1.06 per share, against USD 22.9 million, or USD 0.41 per share.
SP001 License and Pipeline
On July 8, 2026, the company entered into a license agreement with Innovent Biologics (Suzhou) Co., Ltd. and Fortvita Biologics (USA), Inc. for SP001, a third-generation, fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40 Ligand. The license is exclusive worldwide rights to research, develop, manufacture and commercialize SP001 and certain backup and derivative antibodies, excluding mainland China, Taiwan, Hong Kong and Macau.
The company paid Innovent a USD 35.0 million upfront payment in August 2026, recorded as acquired in-process research and development expense, and is obligated to pay aggregate milestone payments of up to approximately USD 1.05 billion on the achievement of certain development, regulatory and commercial milestones. It accounted for the purchase as an asset acquisition.
The filing also states that on June 17, 2026, the company and GSK announced the FDA approved Utebzi, an oral antibiotic for complicated urinary tract infections, including pyelonephritis, in adult patients who have limited or no alternative oral treatment options. The filing notes that, on December 31, 2025, the company agreed with Pfizer to terminate the Pfizer License Agreement for SPR206.
Financing, Cash and Liquidity
On July 8, 2026, the company entered into a USD 105.0 million non-recourse, non-dilutive milestone and royalty financing transaction with affiliates of Healthcare Royalty Management, LLC, under which HCRx receives a portion of future GSK proceeds. At September 30, 2026, the Liability related to the sale of future milestones and royalties was USD 50.8 million current and USD 52.3 million long-term.
Cash and cash equivalents were USD 107.9 million at September 30, 2026. Net cash used in Operating Activities for the nine months was USD 32.1 million, against USD 4.3 million, and net cash provided by financing activities was USD 99.8 million, with none in the prior-year period. Total liabilities were USD 109.2 million, against USD 9.9 million at December 31, 2025.
The company states it believes its cash and cash equivalents as of September 30, 2026 are sufficient to fund operating expenses and Capital Expenditure requirements for at least 12 months from the issuance of the financial statements and into the second half of 2029. It adds that this timeline is uncertain and subject to change as it explores opportunities to grow its program, and that it would need additional funding beyond that point or if it changes its operating plan.
At September 30, 2026, 58,237,077 shares of common stock were outstanding, against 56,414,657 at December 31, 2025. Stockholders approved a 2026 Stock Incentive Plan on June 23, 2026, and 5,874,475 shares were available for grant under it at quarter-end.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...